Recent Advances in Cancer and Eye Disease Management

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts life sciences trends across cancer and eye disease management. The corresponding clinical trials scenario is depicted along with industry interactions. A summary of key clinical trials using BMS-986016 therapy is also presented.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing t

Table of Contents

Recent Advances in Cancer and Eye Disease ManagementBiotechnological Innovations for Cancer and Eye DiseasesNext-generation Cancer ImmunotherapyEnhancing the Efficacy of Immune Checkpoint InhibitorsNovel Aldehyde Trapping Platform for Eye DisordersNovel Oncoprotein Candidate for Childhood CancerClinical Trial Analysis and Industry InteractionsSummary of Key Clinical Trials Using BMS-986016 TherapySummary of Key Clinical Trials Using BMS-986016 Therapy (continued)Summary of Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.